Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: August 18, 2011
Last updated: March 29, 2012
Last verified: March 2012

The purpose of this study is to assess the pharmacodynamic (PD) effects (Total Symptom Score (TSS) and its individual components: rhinorrhoea, nasal congestion, post-nasal drip) of intranasal, repeat dose SB-705498 in non-allergic rhinitis (NAR) patients elicited by a cold dry air challenge in an environmental exposure chamber (EEC). SB-705498 is a selective antagonist of the transient receptor potential vanilloid-1 (TRPV1) ligand gated ion channel. TRPV1 is a cation permeable ion channel that can be activated by several physiological factors, such as heat, protons (pH), osmotic stress, eicosanoid derivatives, anandamide, and by products of inflammation, such as histamine, prostaglandins and bradykinin. In the nose, the local TRPV1 expressing sensory C-fibres are thought to play a key role in the development of nasal hyper-responsiveness to environmental provocateurs. It has been proposed that blocking the nasal sensory nerve stimulation may control nasal hyper-responsiveness and therefore prevent the induction of rhinitis symptoms. In this context, preclinical evidence supports that targeting TRPV1 by SB-705498 may be an attractive option.

In this study NAR patients will be randomised, in a double blind, placebo controlled cross over design to receive 14 day repeat doses of 12mg intra-nasal SB-705498 once daily. Whilst dosing at home, subjects will record symptom scores to document their symptoms. In addition, during visits to the clinical unit, acoustic rhinometry, quality of life questionnaires and safety assessments will be monitored.

Condition Intervention Phase
Non-allergic Rhinitis
Drug: SB-705498
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind Placebo Controlled, 2 Way Cross Over Study in Adults With Non-allergic Rhinits to Evaluate the Effect of Once Daily Administration of Intranasal SB-705498 12mg for Two Weeks and the Response to a Chamber Challenge of Cold Dry Air

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • TSS scores on SB-705498 compared to placebo [ Time Frame: day 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of adverse events [ Time Frame: day 1 to day 14 inclusive ] [ Designated as safety issue: Yes ]
  • TSS scores following SB-705498 compared to placebo [ Time Frame: Day 1-14 ] [ Designated as safety issue: No ]
  • Effect of SB-705498 on sneezing [ Time Frame: Day 1 and Day 14 ] [ Designated as safety issue: No ]
  • Acoustic rhinometry (AR) changes from baseline to D14 [ Time Frame: Day 1 and Day 14 ] [ Designated as safety issue: No ]
  • Rhinoconjunctivits Quality of Life Questionnaire (RQLQ) following repeat doses of SB-705498 [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • Effect of SB-705498 on ocular symptom scores compared to placebo [ Time Frame: Day 1 and Day 14 ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: December 2010
Study Completion Date: May 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SB-705498 Drug: SB-705498
12mg intra nasal
Placebo Comparator: Placebo Drug: Placebo
Placebo intra nasal


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  1. Diagnosis of NAR, as determined by the presence of perennial rhinitis symptoms that last for several months per year, for more than 1 year and are not attributed to allergy, infections or nasal abnormalities. Positive history of rhinitis symptoms triggered by environmental provocateurs (e.g. weather changes, irritants, air pollution etc), but not allergens.
  2. Normal levels of total plasma IgE and negative allergy skin or Rast tests to common aeroallergens.
  3. Male or female between 18 and 65 years of age inclusive.
  4. A female subject is eligible to participate if she is of:

    • Non-childbearing potential defined as pre-menopausal females with a \documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
    • Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 84 days post-last treatment administration.
  5. Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 8.1. This criterion must be followed from the time of the first dose of study medication until 84 days post-last treatment administration.
  6. Body weight ≥ 50 kg (males) and ≥45kg (females) and BMI within the range 19 - 29.9 kg/m2 (inclusive).
  7. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  8. Available to complete all the required study measurements.
  9. Single QTc, < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
  10. The subject must demonstrate at screening TSS ≥ 4 (on a 9 point scale) at screening visits 1 and 2.
  11. AST and ALT < 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

Exclusion Criteria:

Deviations from exclusion criteria are not allowed because they can potentially jeopardise the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Nasal abnormalities likely to affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, other nasal malformations.
  2. History of frequent nosebleeds.
  3. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  4. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  5. Positive pre-study drug/alcohol/smoking screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, benzodiazepines and methadone
  6. A positive test for HIV antibody.
  7. History of regular alcohol consumption within 6 months of the study defined as:

    • An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.

  8. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  9. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  10. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

    Subjects who are using some of the medications below on an as needed basis, may participate in the study if they remain free of medication for the following periods of time prior to each visit:

    • Nasal antihistamines: 48 hours
    • Oral antihistamines A (cetirizine, fexofenadine, loratadine, desloratadine): 7 days
    • Oral antihistamines B (all others): 7 days
    • Nasal decongestants: 24 hours
    • Oral decongestants: 24 hours
    • Nasal glucocorticosteroids: 4 weeks
    • Inhaled glucocorticoids: 4 weeks
    • Oral glucocorticosteroids: 12 weeks
    • Oral leukotriene receptor antagonists: 7 days
    • Oral 5-lipoxygenase inhibitors: 7 days
    • Oral methylxanthines: 7 days Subjects with recent upper respiratory tract infections (URTIs) will be allowed in the study only if their nasal symptoms have been completely resolved for more than 3 weeks prior to screening.
  11. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  12. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  13. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  14. Lactating females.
  15. Unwillingness or inability to follow the procedures outlined in the protocol.
  16. Subject is mentally or legally incapacitated.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01424514

Canada, Ontario
GSK Investigational Site
Mississauga, Ontario, Canada, L4W 1N2
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01424514     History of Changes
Other Study ID Numbers: 114974 
Study First Received: August 18, 2011
Last Updated: March 29, 2012
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Common Cold
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases processed this record on September 29, 2016